Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

About this update from Johnson & Johnson

The Dual Energy THERMOCOOL SMARTTOUCH SF Platform combines pulsed field and radiofrequency energy delivery in a unified and integrated treatment platform i IRVINE, Calif., June 25, 2026 --( BUSINESS WIRE )--Johnson & Johnson today announced the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe, expanding physician access to a dual-energy catheter ablation solution designed for personalized care across workflows, anatomies and procedural strategies.i The platform combines the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, an irrigated contact-force sensing catheter, with the TRUPULSE Generator to enable delivery of both radiofrequency (RF) and pulsed field (PF) energy through a single catheter-based solution.i Designed to support precise and insight-driven ablation, the platform enables electrophysiologists to leverage both pulsed field and radiofrequency energy within the same procedure.i Built on the THERMOCOOL SMARTTOUCH SF platform, a globally trusted catheter with extensive clinical validation and more than a million patients treated worldwide, DE STSF combines a familiar point-by-point workflow with the flexibility to tailor treatment approaches across a broad range of cardiac ablation procedures.i Leveraging the power of CARTO integration, ultra high-density mapping solutions and intracardiac ultrasound imaging, the platform delivers advanced electro-anatomical mapping, catheter visualization, contact-force feedback and PF/RF Index guidance. Together, these capabilities are designed to support procedural control and reproducible lesion creation. "DE STSF is a welcome addition to the EP lab because it allows physicians to incorporate new technology based on the gold RF standard smarttouch SF platform while maintaining familiar workflows with greater versatility by seamlessly switching between RF and PFA," said Nicolas Derval1, M.D., Bordeaux, France. "This flexibility also provides greater ability to adjust treatment to different patient anatomies, clinical needs and procedural goals while increasing safety in ablating the posterior wall for example.i" "No two atrial fibrillation patients are the same, which is why personalized treatment and procedural versatility matter," said Ricardo Martin, President EMEA, Electrophysiology, MedTech, Johnson & Johnson. "The launch of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform reflects our continued commitment to providing physicians with a broad range of treatment options. As the latest addition to our integrated pulsed field ablation portfolio, it combines the familiarity of the world's leading radiofrequency catheter with the versatility of pulsed field ablation, giving physicians greater confidence to tailor treatment to each patient's needs."

View stock analysis, news, and events for Johnson & Johnson